Pay in 4 interest-free payments of $5.31 Learn more
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9
Hims even bought a 503B outsourcing facility in California this fall in order to continue to deliver on sterile compounded products like GLP-1 injections. But in the event the FDA lifts the shortage designation, Hims appears to be counting on the narrower 503A process to justify its investments in compounding
p=0,007) sin heterogeneidad en los estudios (I.= 0%)
As of May 2026, BPC-157 isnt FDA-approved and sits on the FDAs restricted (Category 2) compounding list, so selling it as a drug or supplement is illegal (source)
Progress in nasal drug delivery systems
Feb 2019;69(1):77-81
US$ 24.64
US$ 28.84
US$ 28.21
US$ 20.19
US$ 23.52
US$ 24.27
US$ 29.00
US$ 25.59
US$ 26.61
US$ 22.31
